Regenicin (OTCMKTS:RGIN) and FRESENIUS SE &/S (OTCMKTS:FSNUY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
FRESENIUS SE &/S pays an annual dividend of $0.15 per share and has a dividend yield of 1.3%. Regenicin does not pay a dividend. FRESENIUS SE &/S pays out 19.0% of its earnings in the form of a dividend.
This is a summary of recent recommendations and price targets for Regenicin and FRESENIUS SE &/S, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|FRESENIUS SE &/S||0||3||1||0||2.25|
Risk and Volatility
Regenicin has a beta of 3.54, suggesting that its share price is 254% more volatile than the S&P 500. Comparatively, FRESENIUS SE &/S has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.
This table compares Regenicin and FRESENIUS SE &/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|FRESENIUS SE &/S||5.89%||11.82%||3.57%|
Earnings and Valuation
This table compares Regenicin and FRESENIUS SE &/S’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|FRESENIUS SE &/S||$39.40 billion||0.66||$2.39 billion||$0.79||14.73|
FRESENIUS SE &/S has higher revenue and earnings than Regenicin.
Insider & Institutional Ownership
0.1% of FRESENIUS SE &/S shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
FRESENIUS SE &/S beats Regenicin on 8 of the 10 factors compared between the two stocks.
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. Its development products include NovaDerm, a cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was founded in 2007 and is based in Little Falls, New Jersey.
About FRESENIUS SE &/S
Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis- related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products used in the collection and processing of blood components, as well as in transfusion medicine. The Fresenius Helios segment operates 111 hospitals with approximately 35,000 beds, such as 88 acute care hospitals and 23 post-acute care clinics; 4 post-acute care centers; 17 prevention centers; and 12 nursing homes. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Receive News & Ratings for Regenicin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenicin and related companies with MarketBeat.com's FREE daily email newsletter.